Navigation Links
Enox Biopharma, Inc. to Present at IN3 West Investment in Innovation Conference.
Date:2/22/2011

VANCOUVER, British Columbia, Feb. 22, 2011 /PRNewswire/ -- Enox Biopharma, Inc. CEO, John C. Rewcastle, Ph.D., will present at the IN3 West Investment in Innovation Conference on Thursday, February 24 at 11:05 AM PST. The conference is being held at the Venetian Hotel in Las Vegas.

Dr. Rewcastle will provide an overview of Enox's technology and its ability to embed nitric oxide into polymer medical devices rendering them antimicrobial. He will also review recently published independent data that shows that ionic silver coatings for medical devices are not as effective as hoped.

"There is a very significant clinical need for an effective non-antibiotic treatment to render medical devices antimicrobial," said Rewcastle. "Each year in the United States alone, hospital acquired infections kill hundreds of thousands of patients and cost the health care system tens of billions of dollars. Silver coatings were hoped to be an answer to increasing antibiotic but, based on recent publications, this does not appear to be the case. Our nitric oxide technology is uniquely positioned to answer this critical need of all healthcare systems worldwide."

"The IN3 West Conference is an ideal venue for Enox to present at," continued Rewcastle. "The participants consist of both venture capitalists and larger companies seeking to partner with emerging technologies. I am looking forward to the meeting and expect a very positive response."About Enox Biopharma Inc.Enox Biopharma, Inc. is an emerging biotechnology company with proprietary technology that embeds nitric oxide (NO) into polymer medical devices. The innate immune system uses NO to block microbial growth - embedding NO into medical devices makes them antimicrobial. Enox's technology is applicable to any indwelling polymer medical device including, but not limited to catheters, endotracheal tubes, tympanostomy tubes and cosmetic implants. With the current CMS non-coverage of certain nosocomial infections the financial burden of these infections has shifted to hospitals who are desperately seeking ways to reduce infection rates. By utilizing NO, part of the human body's innate immune system, Enox Biopharma is improving existing medical devices by making them antimicrobial.

Forward Looking Information

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on management's good faith views and expectations when made. Forward-looking statements are inherently subject to known and unknown risks and uncertainties which, in the case of the company, include raising adequate capital to continue operations, technology and product development uncertainties, and competition. Actual financial results of the company may differ, perhaps materially, from those discussed in the forward-looking statements. The company is not obligated, and does not undertake, to update its forward-looking statements or comment on the differences that may develop between its statements and actual results. Readers are encouraged to refer to the recent public filings of the company to further ascertain the risks associated with the forward-looking statements. Readers are urged not to place undue reliance upon such statements.For more information, please contact:John C. Rewcastle, Ph.D., CEO orItamar David, CFOEnoxBiopharma, Inc.604.637.9744 phone888.224.7259 faxinfo@enoxbiopharma.comwww.enoxbiopharma.com
'/>"/>

SOURCE Enox Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
2. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
3. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
4. Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug
5. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Receives New Research Grant From Hong Kong Innovation and Technology Commission
6. Enox Biopharma, Inc. to Present at OneMedForum Emerging Company Finance Conference.
7. Plato BioPharma, Inc Appoints New Board Member
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
10. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... , May 23, 2016 ... reach USD 5.0 billion by 2022, according to a ... generation of medical waste coupled with the lack of ... is expected to drive the demand for reprocessed medical ... devices as compared to that of the original device ...
(Date:5/20/2016)... 20, 2016 ReportsnReports.com adds ... Medical Devices of its online business intelligence library. ... the current state of the Titrator industry. The ... like definitions, classifications, Specifications, applications and industry chain ... like Raw Material Suppliers, Equipment Suppliers, Manufacturing Cost ...
(Date:5/20/2016)... -- According to the 2016 home healthcare market ... affordable healthcare solutions as since the early 2000s, the cost ... like the US, the healthcare cost rose faster than inflation ... index inflation rate stood at an average of 2.04% during ... during the same time period. This can be attributed to ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... (PRWEB) May 24, 2016 -- Grow Healthy Vending, LLC ... Joining the Grow Healthy Advisory Board team are Amanda Katchka, ... mission of our organization and bring talent, expertise and energy to ... continue to expand our footprint as the leader in healthy vending,” ...
(Date:5/24/2016)... ... 2016 , ... Backed by decades of experience, Metroloji Okulu ... the best suited solution to meet regulatory requirements. Their professional staff also performs ... Istanbul. , Metroloji Okulu specializes in MadgeTech’s line of medical and pharmaceutical ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... advancing the science and clinical practice of radiosurgery, is recognizing five medical residents ... radiosurgery (SRS) and stereotactic body radiotherapy (SBRT). The awards will be presented at ...
(Date:5/24/2016)... ... May 24, 2016 , ... Bio-Logic Aqua® Research ... forty years and a trainer for Ageless Grace ( http://www.agelessgrace.com ) to discuss ... on May 16, 2016. , Formerly a Northwestern University Literature Professor, Kinst gravitated ...
(Date:5/24/2016)... ... 24, 2016 , ... In light of recent heavy flooding in Houston, Texas, ... well water throughout the Houston area. , Heavy floodwaters have led to destroyed waterways ... contaminants. Residents may not even be aware of the contamination of their water supply ...
Breaking Medicine News(10 mins):